TY - JOUR
T1 - Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program
AU - Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ)
AU - Penzel, Nora
AU - Polosecki, Pablo
AU - Addington, Jean
AU - Arango, Celso
AU - Asgari-Targhi, Ameneh
AU - Billah, Tashrif
AU - Bouix, Sylvain
AU - Calkins, Monica E.
AU - Campbell, Dylan E.
AU - Cannon, Tyrone D.
AU - Castro, Eduardo
AU - Cho, Kang Ik K.
AU - Coleman, Michael J.
AU - Corcoran, Cheryl M.
AU - Dwyer, Dominic
AU - Frangou, Sophia
AU - Fusar-Poli, Paolo
AU - Glynn, Robert J.
AU - Haidar, Anastasia
AU - Harms, Michael P.
AU - Jacobs, Grace R.
AU - Kambeitz, Joseph
AU - Kapur, Tina
AU - Kelly, Sinead M.
AU - Koutsouleris, Nikolaos
AU - Abhinandan, K. R.
AU - Kucukemiroglu, Saryet
AU - Kwon, Jun Soo
AU - Lewandowski, Kathryn E.
AU - Li, Qingqin S.
AU - Mantua, Valentina
AU - Mathalon, Daniel H.
AU - Mittal, Vijay A.
AU - Nicholas, Spero
AU - Pandina, Gahan J.
AU - Perkins, Diana O.
AU - Potter, Andrew
AU - Reichenberg, Abraham
AU - Reinen, Jenna
AU - Sand, Michael S.
AU - Seitz-Holland, Johanna
AU - Shah, Jai L.
AU - Srinivasan, Vairavan
AU - Srivastava, Agrima
AU - Stone, William S.
AU - Torous, John
AU - Vangel, Mark G.
AU - Wang, Jijun
AU - Wolff, Phillip
AU - Yao, Beier
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 continents. The assessments include domains similar to those acquired in previous CHR studies along with novel domains that are collected longitudinally across a period of 2 years. In parallel with the data acquisition, multidisciplinary teams of experts have been working to formulate the data analysis strategy for the AMP SCZ project. Here, we describe the key principles for the data analysis. The primary AMP SCZ analysis aim is to use baseline clinical assessments and multimodal biomarkers to predict clinical endpoints of CHR individuals. These endpoints are defined for the AMP SCZ study as transition to psychosis (i.e., conversion), remission from CHR syndrome, and persistent CHR syndrome (non-conversion/non-remission) obtained at one year and two years after baseline assessment. The secondary aim is to use longitudinal clinical assessments and multimodal biomarkers from all time points to identify clinical trajectories that differentiate subgroups of CHR individuals. The design of the analysis plan is informed by reviewing legacy data and the analytic approaches from similar international CHR studies. In addition, we consider properties of the newly acquired data that are distinct from the available legacy data. Legacy data are used to assist analysis pipeline building, perform benchmark experiments, quantify clinical concepts and to make design decisions meant to overcome the challenges encountered in previous studies. We present the analytic design of the AMP SCZ project, mitigation strategies to address challenges related to the analysis plan, provide rationales for key decisions, and present examples of how the legacy data have been used to support design decisions for the analysis of the multimodal and longitudinal data. Watch Prof. Ofer Pasternak discuss his work and this article: https://vimeo.com/1023394132?share=copy#t=0.
AB - The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 continents. The assessments include domains similar to those acquired in previous CHR studies along with novel domains that are collected longitudinally across a period of 2 years. In parallel with the data acquisition, multidisciplinary teams of experts have been working to formulate the data analysis strategy for the AMP SCZ project. Here, we describe the key principles for the data analysis. The primary AMP SCZ analysis aim is to use baseline clinical assessments and multimodal biomarkers to predict clinical endpoints of CHR individuals. These endpoints are defined for the AMP SCZ study as transition to psychosis (i.e., conversion), remission from CHR syndrome, and persistent CHR syndrome (non-conversion/non-remission) obtained at one year and two years after baseline assessment. The secondary aim is to use longitudinal clinical assessments and multimodal biomarkers from all time points to identify clinical trajectories that differentiate subgroups of CHR individuals. The design of the analysis plan is informed by reviewing legacy data and the analytic approaches from similar international CHR studies. In addition, we consider properties of the newly acquired data that are distinct from the available legacy data. Legacy data are used to assist analysis pipeline building, perform benchmark experiments, quantify clinical concepts and to make design decisions meant to overcome the challenges encountered in previous studies. We present the analytic design of the AMP SCZ project, mitigation strategies to address challenges related to the analysis plan, provide rationales for key decisions, and present examples of how the legacy data have been used to support design decisions for the analysis of the multimodal and longitudinal data. Watch Prof. Ofer Pasternak discuss his work and this article: https://vimeo.com/1023394132?share=copy#t=0.
UR - https://www.scopus.com/pages/publications/105003426001
U2 - 10.1038/s41537-025-00561-w
DO - 10.1038/s41537-025-00561-w
M3 - Article
AN - SCOPUS:105003426001
SN - 2334-265X
VL - 11
JO - npj Schizophrenia
JF - npj Schizophrenia
IS - 1
M1 - 53
ER -
